WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) announced a high level of interest in Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable at CES 2016. Highlights of the Week include:
Quell was selected as one of 10 finalists in the CES Last Gadget Standing competition
NeuroMetrix was selected to participate in two panel discussions – “The Roadmap to FDA Approval” and “The Future of Wearables”
Quell was selected as one of 10 finalists in the CES Last Gadget Standing competition
NeuroMetrix was selected to participate in two panel discussions – “The Roadmap to FDA Approval” and “The Future of Wearables”